Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) is a major challenge in cancer therapy, often driven by ATP-binding cassette subfamily G member 2 (ABCG2) overexpression.
• Developing effective reversal agents for ABCG2-mediated MDR is crucial for improving chemotherapeutic outcomes.

Purpose of the Study:

• To investigate CC-671, a dual inhibitor of TTK and CLK2, as a potential ABCG2 reversal agent.
• To evaluate the efficacy of CC-671 in overcoming ABCG2-mediated multidrug resistance in lung cancer cells.

Main Methods:

• Cell-based assays using ABCG2-overexpressing lung cancer cells.
• Mechanistic studies to elucidate the mode of action of CC-671.
• Computational molecular docking to predict binding interactions.

Main Results:

• CC-671 demonstrated significant reversal of ABCG2-mediated MDR, enhancing chemotherapy drug efficacy.
• CC-671 functions by inhibiting ABCG2's drug efflux activity, increasing intracellular drug accumulation.
• CC-671 did not affect ABCG2 protein expression or localization.
• Molecular docking indicated high binding affinity of CC-671 to the ABCG2 drug-binding site.

Conclusions:

• CC-671 is a potent ABCG2 reversal agent with potential therapeutic applications.
• The inhibition of ABCG2 drug efflux by CC-671 provides a rationale for its combination with ABCG2 substrate chemotherapeutics to overcome MDR.